Daschle quits to avoid US Senate scrutiny

9 February 2009

Former US Senate Leader Tom Daschle (Democrat, South Dakota) has withdrawn his nomination as Secretary of Health and Human Services, in  an embarrassing development for President Barack Obama, who entered the  Senate in the same year as Sen Daschle was defeated in 2004. In a  statement, the former Senate Leader described himself as no longer  having the "full faith of Congress and the American people," which he  said were the pre-requisites for the task of introducing a national  health care system.

Although the final nail in Mr Daschle's nomination chances was a  combination of revelations about $140,000 in federal taxes owed and his  involvement with a non-profit organization that is under investigation  for alleged violations of charitable status, his activities since 2006  as an unofficial lobbyist on health care issues were also a factor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight